Organon & Co. (OGN) to Release Earnings on Thursday

Organon & Co. (NYSE:OGN) is projected to issue its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect the company to announce earnings of $0.74 per share and revenue of $1.5152 billion for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 12, 2026 at 8:30 AM ET.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Monday, November 10th. The company reported $1.01 earnings per share for the quarter, topping analysts’ consensus estimates of $0.93 by $0.08. Organon & Co. had a net margin of 7.95% and a return on equity of 143.47%. The company had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same period in the prior year, the company posted $1.38 EPS. On average, analysts expect Organon & Co. to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Organon & Co. Stock Down 1.1%

Shares of NYSE:OGN opened at $7.82 on Wednesday. The firm has a market capitalization of $2.03 billion, a PE ratio of 4.07, a price-to-earnings-growth ratio of 1.69 and a beta of 0.58. The business has a 50 day simple moving average of $7.88 and a two-hundred day simple moving average of $8.63. Organon & Co. has a 1 year low of $6.18 and a 1 year high of $17.23. The company has a debt-to-equity ratio of 9.69, a current ratio of 1.75 and a quick ratio of 1.20.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Piper Sandler cut Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 price objective for the company. in a report on Monday, October 27th. Wall Street Zen lowered shares of Organon & Co. from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Barclays started coverage on shares of Organon & Co. in a research note on Tuesday, December 9th. They issued an “underweight” rating and a $7.50 price target on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Organon & Co. from $14.00 to $12.00 and set an “underweight” rating for the company in a research report on Tuesday, November 11th. Finally, Morgan Stanley dropped their target price on shares of Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research note on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and five have assigned a Sell rating to the company. According to MarketBeat, Organon & Co. has a consensus rating of “Reduce” and an average price target of $8.38.

Institutional Investors Weigh In On Organon & Co.

Several large investors have recently modified their holdings of the business. Royal Bank of Canada boosted its stake in shares of Organon & Co. by 53.4% during the first quarter. Royal Bank of Canada now owns 360,862 shares of the company’s stock valued at $5,374,000 after purchasing an additional 125,648 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Organon & Co. by 126.4% during the first quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company’s stock worth $21,370,000 after buying an additional 801,307 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Organon & Co. by 2.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,042,991 shares of the company’s stock valued at $15,530,000 after acquiring an additional 26,640 shares in the last quarter. Focus Partners Wealth increased its holdings in shares of Organon & Co. by 33.2% in the 1st quarter. Focus Partners Wealth now owns 55,875 shares of the company’s stock valued at $832,000 after acquiring an additional 13,925 shares during the period. Finally, XTX Topco Ltd purchased a new position in shares of Organon & Co. in the 2nd quarter valued at $107,000. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.